查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1451061

2024-2032 年按適應症（自體免疫疾病、腫瘤、代謝紊亂等）、類別（重組蛋白、單株抗體、純化蛋白）和地區分類的生物製藥市場報告

Biopharmaceutical Market Report by Indication (Autoimmune Diseases, Oncology, Metabolic Disorders, and Others), Class (Recombinant Proteins, Monoclonal Antibodies, Purified Proteins), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 135 Pages | 商品交期: 2-3個工作天內

價格

2023年全球生物製藥市場規模達到3,005億美元。展望未來， IMARC Group預計到2032年市場規模將達到6,439億美元，2024-2032年複合年成長率（CAGR）為8.6%。對個人化藥物的需求不斷成長、慢性病和生活方式相關疾病的盛行率不斷上升，以及生物技術（包括基因工程和重組 DNA 技術）的快速進步，是推動市場成長的關鍵因素。

生物製藥，也稱為生物製劑，是一類從生物來源衍生出來的藥物。它們是利用細菌、酵母或哺乳動物細胞等活生物體透過生物技術過程生產的。與化學合成的傳統小分子藥物不同，生物製藥是大而複雜的分子，與體內的生物標靶表現出高度特異性的相互作用。與傳統藥物相比，它們具有多種優勢。它們的作用往往具有高度特異性，通常針對特定受體或分子，從而提高療效並減少副作用。此外，生物製藥有可能治療先前使用傳統藥物難以解決的疾病。

由於對個人化醫療的需求不斷成長，該市場正在經歷顯著成長。此外，擴大利用生物製藥來治療癌症、糖尿病、牛皮癬和類風濕性關節炎，這是另一個主要的生長誘導因素。此外，大眾對生物製藥的有效性和可用性的認知不斷增強，這是另一個主要的成長誘導因素。此外，對罕見疾病和孤兒藥的日益關注正在推動市場的成長。這些罕見疾病的特徵通常是患者群體較少，但醫療需求卻未被滿足。除此之外，世界各地的政府和監管機構還推出了激勵措施並簡化了監管流程，以鼓勵開發這些疾病的療法。此外，生物製藥公司正在投資研發，開發針對罕見疾病的孤兒藥，從而滿足關鍵的醫療需求並創造市場擴張機會。

生物製藥市場趨勢/促進因素：

對個人化醫療的需求不斷成長

個人化醫療導致生物製藥市場轉向標靶治療和精準醫療方法。生物製藥公司越來越注重開發針對特定基因突變、生物標記或與疾病相關的分子途徑的療法。此外，個人化醫療帶來了藥物基因組學的進步，藥物基因組學是研究個體的基因組成如何影響其對藥物的反應。了解影響藥物代謝、功效和安全性的遺傳變異可以識別可能面臨不良反應風險的患者或更有可能對特定治療產生良好反應的患者。這些知識使生物製藥公司能夠開發針對個別患者的針對性療法和劑量方案，從而提高治療效果並降低不良事件的風險。

慢性病和生活方式相關疾病的盛行率不斷上升

慢性疾病，包括心血管疾病、糖尿病、癌症、呼吸系統疾病和自體免疫疾病，已成為全球主要的健康挑戰。這些疾病往往具有複雜的潛在機制，需要有針對性和個人化的治療方法。生物製藥，如單株抗體、重組蛋白和基因療法，提供精確的標靶和客製化的治療選擇。這些療法可以針對與慢性疾病相關的特定分子途徑、受體或細胞，從而提高療效並減少副作用。此外，慢性病和生活方式相關疾病的負擔日益增加，已將重點從症狀緩解轉向疾病改變和預防，這也推動了市場的成長。

生物技術的各種進步

生物技術大大加速了藥物發現和開發進程。高通量篩選、組合化學和計算建模等先進技術可以在更短的時間內鑑定和測試大量候選藥物。這提高了藥物發現的效率和速度，使生物製藥公司能夠更快地將新療法推向市場。此外，分析個別基因組成、識別疾病標記和了解分子途徑的能力使得能夠開發針對特定患者群體的標靶療法。基因組學、下一代定序和基因編輯技術等生物技術工具徹底改變了對疾病機制的理解，並促進了針對特定遺傳變異和分子標靶的療法的開發，從而推動了市場的發展。

目錄

第1章：前言

第 2 章：範圍與方法

  • 研究目的
  • 利害關係人
  • 資料來源
    • 主要資源
    • 二手資料
  • 市場預測
    • 自下而上的方法
    • 自上而下的方法
  • 預測方法

第 3 章：執行摘要

第 4 章：簡介

第 5 章：全球生物製藥市場

  • 市場表現與預測
    • 目前業績（2018-2023）
    • 市場預測（2024-2032）
  • COVID-19 的影響
  • 市場：按地區
    • 目前業績（2018-2023）
    • 市場預測（2024-2032）
  • 市場：按指標
    • 自體免疫疾病
    • 腫瘤學
    • 代謝紊亂
    • 其他
  • 市場：按類別
    • 重組蛋白
      • 目前業績（2018-2023）
      • 市場預測（2024-2032）
    • 單株抗體
      • 目前業績（2018-2023）
      • 市場預測（2024-2032）
    • 純化蛋白質
      • 目前業績（2018-2023）
      • 市場預測（2024-2032）
  • 競爭格局
    • 頂尖生物製藥公司
    • 頂級生物製藥
  • 價值鏈分析
  • 波特五力分析
    • 概述
    • 買家的議價能力
    • 供應商的議價能力
    • 競爭程度
    • 新進入者的威脅
    • 替代品的威脅

第 6 章：北美

  • 美國
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 加拿大
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）

第 7 章：拉丁美洲

  • 墨西哥
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 巴西
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 阿根廷
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）

第 8 章：歐洲

  • 德國
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 法國
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 義大利
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 西班牙
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 英國
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 俄羅斯
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 土耳其
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）

第 9 章：亞太地區

  • 日本
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 中國
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 澳洲
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 韓國
    • 市場表現（2018-2023）
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 印度
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）
  • 印尼
    • 市場表現（2018-2023）
    • 市場：按類別
      • 重組蛋白
      • 單株抗體
      • 純化蛋白質
    • 頂尖選手
    • 市場預測（2024-2032）

第 10 章：SWOT 分析

  • 概述
  • 優勢
  • 弱點
  • 機會
  • 威脅

第 11 章：競爭格局

  • 市場結構
  • 關鍵參與者
  • 關鍵參與者簡介
    • AbbVie Inc.
    • Amgen Inc
    • Biogen Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Johnson & Johnson
    • Merck & Co. Inc.
    • Novo Nordisk A/S
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112024A722

The global biopharmaceutical market size reached US$ 300.5 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 643.9 Billion by 2032, exhibiting a growth rate (CAGR) of 8.6% during 2024-2032. The escalating demand for personalized medicines, the growing prevalence of chronic and lifestyle-related diseases, and rapid advancements in biotechnology, including genetic engineering and recombinant DNA technology, are among the key factors driving the market growth.

Biopharmaceuticals, also known as biologics, are a class of pharmaceutical drugs derived from biological sources. They are produced using living organisms, such as bacteria, yeast, or mammalian cells, through biotechnological processes. Unlike traditional small-molecule drugs, which are chemically synthesized, biopharmaceuticals are large, complex molecules that exhibit highly specific interactions with biological targets in the body. They offer several advantages over traditional pharmaceuticals. They tend to be highly specific in their action, often targeting specific receptors or molecules, resulting in increased efficacy and reduced side effects. Additionally, biopharmaceuticals have the potential to treat diseases that were previously challenging to address using conventional drugs.

The market is experiencing significant growth due to the escalating demand for personalized medicine. In addition, the increasing utilization of biopharmaceuticals to treat cancer, diabetes, psoriasis, and rheumatoid arthritis represents another major growth-inducing factor. Besides, the growing awareness among the masses regarding the effectiveness and availability of biopharmaceuticals represents another major growth-inducing factor. Moreover, the rising focus on rare diseases and orphan drugs is driving the growth of the market. These rare diseases, often characterized by small patient populations, present significant unmet medical needs. Other than this, governments and regulatory agencies worldwide have introduced incentives and streamlined regulatory processes to encourage the development of therapies for these conditions. Moreover, biopharmaceutical companies are investing in R&D to develop orphan drugs, which target rare diseases, thereby addressing critical medical needs and creating opportunities for market expansion.

Biopharmaceutical Market Trends/Drivers:

The escalating demand for personalized medicine

Personalized medicine has led to a shift toward targeted therapies and precision medicine approaches in the biopharmaceutical market. Biopharmaceutical companies are increasingly focusing on the development of therapies that target specific genetic mutations, biomarkers, or molecular pathways associated with diseases. Moreover, personalized medicine has led to advancements in pharmacogenomics, which is the study of how an individual's genetic makeup influences their response to drugs. Understanding the genetic variations that impact drug metabolism, efficacy, and safety allows for the identification of patients who may be at risk of adverse reactions or those who are more likely to respond favorably to a specific treatment. This knowledge enables biopharmaceutical companies to develop targeted therapies and dosage regimens tailored to individual patients, enhancing treatment effectiveness and reducing the risk of adverse events.

The growing prevalence of chronic and lifestyle-related diseases

Chronic diseases, including cardiovascular disorders, diabetes, cancer, respiratory diseases, and autoimmune conditions, have become major global health challenges. These diseases often have complex underlying mechanisms, requiring targeted and personalized treatment approaches. Biopharmaceuticals, such as monoclonal antibodies, recombinant proteins, and gene therapies, offer precise targeting and tailored treatment options. These therapies can target specific molecular pathways, receptors, or cells associated with chronic diseases, resulting in enhanced efficacy and reduced side effects. Moreover, the increasing burden of chronic and lifestyle-related diseases has shifted the focus from symptomatic relief to disease modification and prevention, which is also propelling the market growth.

Various advancements in biotechnology

Biotechnology has greatly accelerated the drug discovery and development process. Advanced techniques, such as high-throughput screening, combinatorial chemistry, and computational modeling, enable the identification and testing of a large number of drug candidates in a shorter time frame. This has led to an increase in the efficiency and speed of drug discovery, allowing biopharmaceutical companies to bring new therapies to market more rapidly. Besides, the ability to analyze an individual's genetic makeup, identify disease markers, and understand molecular pathways has enabled the development of targeted therapies tailored to specific patient populations. Biotechnology tools, such as genomics, next-generation sequencing, and gene editing techniques, have revolutionized the understanding of disease mechanisms and enabled the development of therapies that address specific genetic variations and molecular targets, thus propelling the market.

Biopharmaceutical Industry Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the global biopharmaceutical market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on indication and class.

Breakup by Indication:

Autoimmune Diseases

Oncology

Metabolic Disorders

Others

Autoimmune diseases represent the leading segment

The report has provided a detailed breakup and analysis of the market based on the indication. This includes autoimmune diseases, oncology, metabolic disorders, and others. According to the report, autoimmune diseases represented the largest segment.

Autoimmune diseases are often chronic and complex conditions that require long-term management and treatment. These diseases can affect multiple organs and systems in the body, leading to a wide range of symptoms and complications. Biopharmaceutical therapies have shown promising results in managing and controlling autoimmune diseases, providing relief from symptoms, slowing disease progression, and improving quality of life for patients. Therapies, including monoclonal antibodies and other biologics, have emerged as a vital treatment option for autoimmune diseases. They target specific molecules, cells, or pathways involved in the autoimmune response, providing more precise and effective therapeutic interventions.

Breakup by Class:

Recombinant Proteins

Monoclonal Antibodies

Purified Proteins

Monoclonal antibodies exhibit a clear dominance in the market

A detailed breakup and analysis of the market based on the class has also been provided in the report. This includes recombinant proteins, monoclonal antibodies, and purified proteins. According to the report, monoclonal antibodies accounted for the largest market share.

Monoclonal antibodies are highly specific in targeting disease-specific antigens or cells. They are designed to bind to a specific target with precision, minimizing off-target effects and reducing the risk of adverse reactions. This specificity contributes to their efficacy in treating various diseases, including autoimmune disorders, cancer, inflammatory conditions, and infectious diseases. They also have a wide range of therapeutic applications across different disease areas. They can be used as therapeutic agents on their own or in combination with other treatments. Monoclonal antibodies have been successful in neutralizing pathogens, blocking cell receptors, modulating immune responses, and delivering therapeutic payloads, making them versatile tools for disease management.

Breakup by Region:

North America

United States

Canada

Latin America

Mexico

Brazil

Argentina

Europe

Germany

France

Italy

Spain

United Kingdom

Russia

Turkey

Asia Pacific

Japan

China

Australia

South Korea

India

Indonesia

North America accounts for the majority of market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Latin America (Mexico, Brazil, and Argentina); Europe (Germany, France, Italy, Spain, the United Kingdom, Russia, and Turkey); and Asia Pacific (Japan, China, Australia, South Korea, India, and Indonesia). According to the report, North America was the largest market for biopharmaceuticals.

North America, particularly the United States, boasts a highly developed healthcare infrastructure, including robust research and development capabilities, advanced clinical facilities, and a strong regulatory framework. The region is home to renowned academic institutions, pharmaceutical companies, and research organizations that drive innovation in the biopharmaceutical industry. The presence of these institutions and infrastructure facilitates the development, manufacturing, and commercialization of biopharmaceutical products. The region has a well-established ecosystem that supports biopharmaceutical innovation, including government funding initiatives, research grants, venture capital investments, and collaborations between academia, industry, and research institutes.

Competitive Landscape:

The competitive landscape of the biopharmaceutical market is highly dynamic and competitive, with numerous global and regional players vying for market share. Nowadays, leading biopharmaceutical companies are heavily investing in R&D to discover and develop innovative therapies. They are conducting preclinical and clinical trials, and advance promising candidates through the regulatory approval process. These investments aim to expand their product pipelines, address unmet medical needs, and stay ahead of competitors in terms of therapeutic advancements. They are also forming strategic partnerships and collaborations with academic institutions, research organizations, and other industry players. These alliances enable them to access new technologies, scientific expertise, and complementary resources.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AbbVie Inc.

Amgen Inc

Biogen Inc.

Eli Lilly and Company

F. Hoffmann-La Roche AG

Johnson & Johnson

Merck & Co. Inc.

Novo Nordisk A/S

Pfizer Inc.

Sanofi S.A

Recent Developments:

Pfizer and BioNTech developed and distributed their mRNA-based COVID-19 vaccine, Comirnaty (BNT162b2). The vaccine received emergency use authorizations and has been widely deployed globally, playing a crucial role in combating the COVID-19 pandemic.

Amgen Inc. recently received FDA approval for Lumakras (sotorasib), a targeted therapy for non-small cell lung cancer (NSCLC) with specific genetic mutations.

AbbVie Inc. has made significant advancements in immunology, particularly with its flagship product, Humira (adalimumab). Humira is one of the world's best-selling biologic drugs used to treat autoimmune conditions, including rheumatoid arthritis, psoriasis, and Crohn's disease.

Key Questions Answered in This Report

  • 1. What was the size of the global biopharmaceutical market in 2023?
  • 2. What is the expected growth rate of the global biopharmaceutical market during 2024-2032?
  • 3. What are the key factors driving the global biopharmaceutical market?
  • 4. What has been the impact of COVID-19 on the global biopharmaceutical market?
  • 5. What is the breakup of the global biopharmaceutical market based on the indication?
  • 6. What is the breakup of the global biopharmaceutical market based on the class?
  • 7. What are the key regions in the global biopharmaceutical market?
  • 8. Who are the key players/companies in the global biopharmaceutical market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

5 Global Biopharmaceutical Market

  • 5.1 Market Performance and Forecast
    • 5.1.1 Current Performance (2018-2023)
    • 5.1.2 Market Forecast (2024-2032)
  • 5.2 Impact of COVID-19
  • 5.3 Market by Region
    • 5.3.1 Current Performance (2018-2023)
    • 5.3.2 Market Forecast (2024-2032)
  • 5.4 Market by Indication
    • 5.4.1 Autoimmune Diseases
    • 5.4.2 Oncology
    • 5.4.3 Metabolic Disorders
    • 5.4.4 Others
  • 5.5 Market by Class
    • 5.5.1 Recombinant Proteins
      • 5.5.1.1 Current Performance (2018-2023)
      • 5.5.1.2 Market Forecast (2024-2032)
    • 5.5.2 Monoclonal Antibodies
      • 5.5.2.1 Current Performance (2018-2023)
      • 5.5.2.2 Market Forecast (2024-2032)
    • 5.5.3 Purified Proteins
      • 5.5.3.1 Current Performance (2018-2023)
      • 5.5.3.2 Market Forecast (2024-2032)
  • 5.6 Competitive Landscape
    • 5.6.1 Top Biopharmaceutical Players
    • 5.6.2 Top Biopharmaceutical Drugs
  • 5.7 Value Chain Analysis
  • 5.8 Porter's Five Forces Analysis
    • 5.8.1 Overview
    • 5.8.2 Bargaining Power of Buyers
    • 5.8.3 Bargaining Power of Suppliers
    • 5.8.4 Degree of Rivalry
    • 5.8.5 Threat of New Entrants
    • 5.8.6 Threat of Substitutes

6 North America

  • 6.1 United States
    • 6.1.1 Market Performance (2018-2023)
    • 6.1.2 Market by Class
      • 6.1.2.1 Recombinant Proteins
      • 6.1.2.2 Monoclonal Antibodies
      • 6.1.2.3 Purified Proteins
    • 6.1.3 Top Players
    • 6.1.4 Market Forecast (2024-2032)
  • 6.2 Canada
    • 6.2.1 Market Performance (2018-2023)
    • 6.2.2 Market by Class
      • 6.2.2.1 Recombinant Proteins
      • 6.2.2.2 Monoclonal Antibodies
      • 6.2.2.3 Purified Proteins
    • 6.2.3 Top Players
    • 6.2.4 Market Forecast (2024-2032)

7 Latin America

  • 7.1 Mexico
    • 7.1.1 Market Performance (2018-2023)
    • 7.1.2 Market by Class
      • 7.1.2.1 Recombinant Proteins
      • 7.1.2.2 Monoclonal Antibodies
      • 7.1.2.3 Purified Proteins
    • 7.1.3 Top Players
    • 7.1.4 Market Forecast (2024-2032)
  • 7.2 Brazil
    • 7.2.1 Market Performance (2018-2023)
    • 7.2.2 Market by Class
      • 7.2.2.1 Recombinant Proteins
      • 7.2.2.2 Monoclonal Antibodies
      • 7.2.2.3 Purified Proteins
    • 7.2.3 Top Players
    • 7.2.4 Market Forecast (2024-2032)
  • 7.3 Argentina
    • 7.3.1 Market Performance (2018-2023)
    • 7.3.2 Market by Class
      • 7.3.2.1 Recombinant Proteins
      • 7.3.2.2 Monoclonal Antibodies
      • 7.3.2.3 Purified Proteins
    • 7.3.3 Top Players
    • 7.3.4 Market Forecast (2024-2032)

8 Europe

  • 8.1 Germany
    • 8.1.1 Market Performance (2018-2023)
    • 8.1.2 Market by Class
      • 8.1.2.1 Recombinant Proteins
      • 8.1.2.2 Monoclonal Antibodies
      • 8.1.2.3 Purified Proteins
    • 8.1.3 Top Players
    • 8.1.4 Market Forecast (2024-2032)
  • 8.2 France
    • 8.2.1 Market Performance (2018-2023)
    • 8.2.2 Market by Class
      • 8.2.2.1 Recombinant Proteins
      • 8.2.2.2 Monoclonal Antibodies
      • 8.2.2.3 Purified Proteins
    • 8.2.3 Top Players
    • 8.2.4 Market Forecast (2024-2032)
  • 8.3 Italy
    • 8.3.1 Market Performance (2018-2023)
    • 8.3.2 Market by Class
      • 8.3.2.1 Recombinant Proteins
      • 8.3.2.2 Monoclonal Antibodies
      • 8.3.2.3 Purified Proteins
    • 8.3.3 Top Players
    • 8.3.4 Market Forecast (2024-2032)
  • 8.4 Spain
    • 8.4.1 Market Performance (2018-2023)
    • 8.4.2 Market by Class
      • 8.4.2.1 Recombinant Proteins
      • 8.4.2.2 Monoclonal Antibodies
      • 8.4.2.3 Purified Proteins
    • 8.4.3 Top Players
    • 8.4.4 Market Forecast (2024-2032)
  • 8.5 United Kingdom
    • 8.5.1 Market Performance (2018-2023)
    • 8.5.2 Market by Class
      • 8.5.2.1 Recombinant Proteins
      • 8.5.2.2 Monoclonal Antibodies
      • 8.5.2.3 Purified Proteins
    • 8.5.3 Top Players
    • 8.5.4 Market Forecast (2024-2032)
  • 8.6 Russia
    • 8.6.1 Market Performance (2018-2023)
    • 8.6.2 Market by Class
      • 8.6.2.1 Recombinant Proteins
      • 8.6.2.2 Monoclonal Antibodies
      • 8.6.2.3 Purified Proteins
    • 8.6.3 Top Players
    • 8.6.4 Market Forecast (2024-2032)
  • 8.7 Turkey
    • 8.7.1 Market Performance (2018-2023)
    • 8.7.2 Market by Class
      • 8.7.2.1 Recombinant Proteins
      • 8.7.2.2 Monoclonal Antibodies
      • 8.7.2.3 Purified Proteins
    • 8.7.3 Top Players
    • 8.7.4 Market Forecast (2024-2032)

9 Asia Pacific

  • 9.1 Japan
    • 9.1.1 Market Performance (2018-2023)
    • 9.1.2 Market by Class
      • 9.1.2.1 Recombinant Proteins
      • 9.1.2.2 Monoclonal Antibodies
      • 9.1.2.3 Purified Proteins
    • 9.1.3 Top Players
    • 9.1.4 Market Forecast (2024-2032)
  • 9.2 China
    • 9.2.1 Market Performance (2018-2023)
    • 9.2.2 Market by Class
      • 9.2.2.1 Recombinant Proteins
      • 9.2.2.2 Monoclonal Antibodies
      • 9.2.2.3 Purified Proteins
    • 9.2.3 Top Players
    • 9.2.4 Market Forecast (2024-2032)
  • 9.3 Australia
    • 9.3.1 Market Performance (2018-2023)
    • 9.3.2 Market by Class
      • 9.3.2.1 Recombinant Proteins
      • 9.3.2.2 Monoclonal Antibodies
      • 9.3.2.3 Purified Proteins
    • 9.3.3 Top Players
    • 9.3.4 Market Forecast (2024-2032)
  • 9.4 South Korea
    • 9.4.1 Market Performance (2018-2023)
      • 9.4.1.1 Recombinant Proteins
      • 9.4.1.2 Monoclonal Antibodies
      • 9.4.1.3 Purified Proteins
    • 9.4.2 Top Players
    • 9.4.3 Market Forecast (2024-2032)
  • 9.5 India
    • 9.5.1 Market Performance (2018-2023)
    • 9.5.2 Market by Class
      • 9.5.2.1 Recombinant Proteins
      • 9.5.2.2 Monoclonal Antibodies
      • 9.5.2.3 Purified Proteins
    • 9.5.3 Top Players
    • 9.5.4 Market Forecast (2024-2032)
  • 9.6 Indonesia
    • 9.6.1 Market Performance (2018-2023)
    • 9.6.2 Market by Class
      • 9.6.2.1 Recombinant Proteins
      • 9.6.2.2 Monoclonal Antibodies
      • 9.6.2.3 Purified Proteins
    • 9.6.3 Top Players
    • 9.6.4 Market Forecast (2024-2032)

10 SWOT Analysis

  • 10.1 Overview
  • 10.2 Strengths
  • 10.3 Weaknesses
  • 10.4 Opportunities
  • 10.5 Threats

11 Competitive Landscape

  • 11.1 Market Structure
  • 11.2 Key Players
  • 11.3 Profiles of Key Players
    • 11.3.1 AbbVie Inc.
    • 11.3.2 Amgen Inc
    • 11.3.3 Biogen Inc.
    • 11.3.4 Eli Lilly and Company
    • 11.3.5 F. Hoffmann-La Roche AG
    • 11.3.6 Johnson & Johnson
    • 11.3.7 Merck & Co. Inc.
    • 11.3.8 Novo Nordisk A/S
    • 11.3.9 Pfizer Inc.
    • 11.3.10 Sanofi S.A

List of Figures

  • Figure 1: Global: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 2: Complexity of Biopharmaceuticals
  • Figure 3: Sources of Biopharmaceuticals
  • Figure 4: Global: Biopharmaceutical Market: Value Trends (in Billion US$), 2018-2023
  • Figure 5: Global: Biopharmaceutical Market Forecast: Value Trends (in Billion US$), 2024-2032
  • Figure 6: Global: Biopharmaceutical Market: Sales Share by Country (in %), 2023
  • Figure 7: Global: Biopharmaceutical Market Forecast: Sales Share by Country (in %), 2032
  • Figure 8: Global: Biopharmaceutical Market: Sales Share by Indication (in %), 2023
  • Figure 9: Global: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 10: Global: Biopharmaceutical Market Forecast: Sales by Class (in Million US$), 2024-2032
  • Figure 11: Global: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 12: Global: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 13: Global: Recombinant Proteins Market Forecast (in Million US$), 2024-2032
  • Figure 14: Global: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 15: Global: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 16: Global: Monoclonal Antibodies Market Forecast (in Million US$), 2024-2032
  • Figure 17: Global: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 18: Global: Purified Proteins Market: Sales Share by Class (in %), 2023
  • Figure 19: Global: Purified Proteins Market Forecast (in Million US$), 2024-2032
  • Figure 20: Global: Biopharmaceutical Market: Sales Share of Top Biopharmaceuticals (in %)
  • Figure 21: Global: Biopharmaceutical Industry: Value Chain Analysis
  • Figure 22: Global: Biopharmaceutical Industry: Porter's Five Forces Analysis
  • Figure 23: United States: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 24: United States: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 25: United States: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 26: United States: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 27: United States: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 28: United States: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 29: United States: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 30: United States: Purified Proteins Market: Sales Share by Class (in %), 2023
  • Figure 31: United States: Biopharmaceutical Market: Sales Share of Top Players (in %), 2023
  • Figure 32: United States: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 33: United States: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 34: Canada: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 35: Canada: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 36: Canada: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 37: Canada: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 38: Canada: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 39: Canada: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 40: Canada: Biopharmaceutical Market: Sales Share of Top Players (in %), 2023
  • Figure 41: Canada: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 42: Canada: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 43: Mexico: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 44: Mexico: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 45: Mexico: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 46: Mexico: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 47: Mexico: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 48: Mexico: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 49: Mexico: Purified Proteins Market (in '000 US$), 2018-2023
  • Figure 50: Mexico: Biopharmaceutical Market: Sales Share of Top Players (in %), 2023
  • Figure 51: Mexico: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 52: Mexico: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 53: Brazil: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 54: Brazil: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 55: Brazil: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 56: Brazil: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 57: Brazil: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 58: Brazil: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 59: Brazil: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 60: Brazil: Biopharmaceutical Market: Sales Share of Top Players (in %), 2023
  • Figure 61: Brazil: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 62: Brazil: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 63: Argentina: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 64: Argentina: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 65: Argentina: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 66: Argentina: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 67: Argentina: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 68: Argentina: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 69: Argentina: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 70: Argentina: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 71: Argentina: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 72: Argentina: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 73: Germany: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 74: Germany: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 75: Germany: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 76: Germany: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 77: Germany: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 78: Germany: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 79: Germany: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 80: Germany: Purified Proteins Market: Sales Share by Class (in %), 2023
  • Figure 81: Germany: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 82: Germany: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 83: Germany: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 84: France: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 85: France: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 86: France: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 87: France: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 88: France: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 89: France: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 90: France: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 91: France: Biopharmaceutical Market: Sales Share of Top Players (in %), 2023
  • Figure 92: France: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 93: France: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 94: Italy: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 95: Italy: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 96: Italy: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 97: Italy: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 98: Italy: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 99: Italy: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 100: Italy: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 101: Italy: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 102: Italy: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 103: Italy: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 104: Spain: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 105: Spain: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 106: Spain: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 107: Spain: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 108: Spain: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 109: Spain: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 110: Spain: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 111: Spain: Purified Proteins Market: Sales Share by Class (in %), 2023
  • Figure 112: Spain: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 113: Spain: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 114: Spain: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 115: UK: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 116: UK: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 117: UK: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 118: UK: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 119: UK: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 120: UK: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 121: UK: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 122: UK: Purified Proteins Market: Sales Share by Class (in %), 2023
  • Figure 123: UK: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 124: UK: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 125: UK: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 126: Russia: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 127: Russia: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 128: Russia: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 129: Russia: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 130: Russia: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 131: Russia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 132: Russia: Purified Proteins Market: (in Million US$), 2018-2023
  • Figure 133: Russia: Purified Proteins Market: Sales Share by Class (in %), 2023
  • Figure 134: Russia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 135: Russia: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 136: Russia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 137: Turkey: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 138: Turkey: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 139: Turkey: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 140: Turkey: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 141: Turkey: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 142: Turkey: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 143: Turkey: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 144: Turkey: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 145: Turkey: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 146: Japan: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 147: Japan: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 148: Japan: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 149: Japan: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 150: Japan: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 151: Japan: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 152: Japan: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 153: Japan: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 154: Japan: Biopharmaceutical Market Forecast: Value trend (in Million US$), 2024-2032
  • Figure 155: Japan: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 156: China: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 157: China: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 158: China: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 159: China: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 160: China: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 161: China: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 162: China: Purified Proteins Market: (in Million US$), 2018-2023
  • Figure 163: China: Purified Proteins Market: Sales Share by Class (in %), 2023
  • Figure 164: China: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 165: China: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 166: China: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 167: Australia: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 168: Australia: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 169: Australia: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 170: Australia: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 171: Australia: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 172: Australia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 173: Australia: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 174: Australia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 175: Australia: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 176: Australia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 177: South Korea: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 178: South Korea: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 179: South Korea: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 180: South Korea: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 181: South Korea: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 182: South Korea: Monoclonal Antibodies Market: Sales Share by Class, (in %), 2023
  • Figure 183: South Korea: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 184: South Korea: Purified Proteins Market: Sales Share by Class (in %), 2023
  • Figure 185: South Korea: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 186: South Korea: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 187: South Korea: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 188: India: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 189: India: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 190: India: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 191: India: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 192: India: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 193: India: Purified Proteins Market (in Million US$), 2018-2023
  • Figure 194: India: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 195: India: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 196: India: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 197: Indonesia: Biopharmaceutical Market (in Million US$), 2018-2023
  • Figure 198: Indonesia: Biopharmaceutical Market: Sales by Class (in Million US$), 2018-2023
  • Figure 199: Indonesia: Recombinant Proteins Market (in Million US$), 2018-2023
  • Figure 200: Indonesia: Recombinant Proteins Market: Sales Share by Class (in %), 2023
  • Figure 201: Indonesia: Monoclonal Antibodies Market (in Million US$), 2018-2023
  • Figure 202: Indonesia: Monoclonal Antibodies Market: Sales Share by Class (in %), 2023
  • Figure 203: Indonesia: Biopharmaceutical Market: Sales Share of Top Players (in %)
  • Figure 204: Indonesia: Biopharmaceutical Market Forecast (in Million US$), 2024-2032
  • Figure 205: Indonesia: Biopharmaceutical Market Forecast: Sales Share by Class (in %), 2032
  • Figure 206: Global: Share of Biopharmaceuticals & Small Molecule Drugs Among the Top Ten Selling Drugs (in %), 2001 & 2022
  • Figure 207: Using a Different Manufacturing Process Makes it Extremely Difficult for Biosimilars to be Equivalent to Originator Products
  • Figure 208: Marked Differences Between Biosimilar and Branded Biopharmaceuticals When a Different Production Process was Used
  • Figure 209: Transition Probabilities of Biopharmaceuticals & Small Molecule Drugs in Clinical Phases, (in %)
  • Figure 210: Comparison of the Average Annual Cost of Therapy Using Biopharmaceuticals and Small Molecule Drugs (in US$)
  • Figure 211: Emerging Biopharmaceutical Market Forecast (in Million US$), 2023 & 2032
  • Figure 212: Developed Biopharmaceutical Market Forecast (in Million US$), 2023 & 2032
  • Figure 213: Breakup of Biopharmaceuticals and Small Molecule Drugs Receiving FDA Approval (in Numbers), 2002-2022
  • Figure 214: A Comparison of the Costs Incurred While Developing Biopharmaceuticals and Small Molecule Drugs (in Million US$)
  • Figure 215: Comparison of the Research & Development Times for Biopharmaceuticals & Small Molecule Drugs (in Months)

List of Tables

  • Table 1: Global: Biopharmaceutical Market: Definition & Segmentation
  • Table 2: Global: Biopharmaceutical Market: SWOT Analysis
  • Table 3: Global: Biopharmaceutical Market Forecast: Sales by Region (in Million US$), 2023 & 2032
  • Table 4: Differences Between Small Molecule Drugs & Biopharmaceuticals
  • Table 5: Complexity of Manufacturing Process Involved with Biopharmaceuticals & Small Molecule Drugs
  • Table 6: Global: Biopharmaceutical Market: Sales by Country (in Million US$), 2018-2023
  • Table 7: Global: Biopharmaceutical Market Forecast: Sales by Country (in Million US$), 2024-2032
  • Table 8: Global: Biopharmaceutical Market: Sales by Indication (in Billion US$), 2023
  • Table 9: Mode of Administration of Popular Biotech Drugs